- Kraft Heinz CEO doesn't want long-term M&A regrets amid Campbell Soup speculation
- Kraft Heinz passed on Pinnacle Foods and that means it may not want to buy Campbell Soup
- GrubHub surges after earnings report and LevelUp acquisition
- AT&T falls after missing on revenue in first results since Time Warner deal close
- GlaxoSmithKline shares jump after report of possible break-up
Chinese e-commerce giant Alibaba will inject some of its online pharmacy business into a listed unit in a deal valued at HK$10.6 billion ($1.35 billion), the firm said in a statement on Tuesday.
Alibaba Health Information Technology will buy Ali JK Nutritional Products, which controls sales of medical devices, health-care products, adult products, and health-care services on Alibaba’s Tmall platform.
The deal will see parent Alibaba receive newly issued shares in Ali Health, taking its economic interest in the firm to 56.2 percent from 48.1 percent currently. Alibaba will also have a 67.5 percent voting interest in Ali Health after the deal.
The deal should bolster business for Ali Health amid a broader push into a fast-growing health-care technology market by other firms in China, such as Tencent-backed WeDoctor and recently listed Ping An Healthcare.
Alibaba CEO Daniel Zhang said in a statement that health care was a “strategically important” business area for the firm and that the deal would help turn Ali Health into the country’s “best health-care ecosystem.”
Ali Health’s CEO added that the deal would help the firm expand by adding new categories to its offering.
Chinese health-care spending is set to hit $1 trillion by 2020, up from $357 billion in 2011, according to consultancy McKinsey & Co., with technology firms increasingly looking to break into a growing private health-care market.
The business unit being injected into Ali Health generated a gross merchandise volume of around 20.56 billion yuan ($3.21 billion) in the financial year to March 31 and had over 3,300 related merchants, Ali Health said in a statement.
Alibaba said the deal was subject to approval from Ali Health shareholders and the Hong Kong stock exchange.